EUCTR2019-004940-31-DK进行中（未招募）1 期
Effect of timing of enzyme replacement therapy (Creon®) at meals on fat malabsorption in adult patients with cystic fibrosis - a cross-over trial
Terese Katzenstein0 个研究点目标入组 30 人开始时间: 2020年3月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Outpatient adults of legal age (=18 years)
- •with cystic fibrosis and pancreatic
- •insufficiency and who takes enzyme
- •replacement therapy (Creon®) with every fat
- •containing meal of the day.
- •- The patients must be able to physically
- •attend the planned trial days once a month.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 29
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •- Acutely ill outpatient and inpatient CF
- •patients with other disease of impact on
- •primary outcome (i.e. obstipation that
- •requires treatment and/or acute lung
- •exacerbation).
- •- Pregnancy.
- •- BMI below 18,5.
- •- Nonattendance from planned trial days without possibility of rescheduling within a week.
研究者
相似试验
已完成
不适用
Efficacy and safety of enzyme replacement therapy for MPS I with 100 I.U./Kg recombinant human a-L-iduronidase (ALDURAZYME™).Mucopolysaccharidose type I.NL-OMON21663CVZ35
已完成
不适用
Efficacy and safety of enzyme replacement therapy for Mucopolysaccharidosis type I with 100 IU/Kg recombinant human a-L-iduronidase (Aldurazyme™)Mucopolysaccharidosis type INutritional, Metabolic, EndocrineDisorders of metabolismISRCTN22324060Erasmus Medical Centre (The Netherlands)35
招募中
3 期
The effect of pancratic enzyme replacement therapy on anthropometric criteria in children with failure to thriveIRCT20230313057703N1Rasht University of Medical Sciences60
招募中
不适用
Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)Fabry's DiseaseNCT02469181Yonsei University20
招募中
4 期
atural course, effects of enzyme therapy and health economic aspects in patients with mucopolysaccharidosis type I, II and VI. Long-term folloe-up of untreated patients and patients receiving commercially available Aldurazyme, Elaprase and Naglazyme.Hunter syndrome and Maroteaux-Lamy syndrome)lysosomal storage disorders (Hurler syndrome100274241002160510028396NL-OMON35691Erasmus MC, Universitair Medisch Centrum Rotterdam50